R S Rittmaster

Summary

Affiliation: Glaxo Wellcome
Country: USA

Publications

  1. ncbi request reprint Antiandrogen treatment of polycystic ovary syndrome
    R S Rittmaster
    Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina, USA
    Endocrinol Metab Clin North Am 28:409-21. 1999
  2. ncbi request reprint Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
    R S Rittmaster
    Department of Medicine and the Queen Elizabeth II Health Sciences Center, Dalhousie University, Halifax, Nova Scotia, Canada
    J Clin Endocrinol Metab 85:2129-34. 2000
  3. ncbi request reprint The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer
    R S Rittmaster
    Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
    J Urol 162:2165-9. 1999
  4. ncbi request reprint Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase
    A S Wright
    Department of Physiology and Biophysics, Dalhousie University, Halifax, Nova Scotia, Canada
    Endocrinology 140:4509-15. 1999
  5. ncbi request reprint Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5
    L N Thomas
    Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
    Prostate 42:203-10. 2000
  6. ncbi request reprint Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer
    Lynn N Thomas
    Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada
    Prostate 63:231-9. 2005
  7. ncbi request reprint Testolactone-associated high androgen levels, a pharmacologic effect or a laboratory artifact?
    E A Cummings
    Department of Pediatrics, IWK Grace Health Centre, Halifax, Nova Scotia, Canada
    J Clin Endocrinol Metab 83:784-7. 1998
  8. ncbi request reprint Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line
    C B Lazier
    Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, NS, Canada
    Prostate 58:130-44. 2004

Detail Information

Publications8

  1. ncbi request reprint Antiandrogen treatment of polycystic ovary syndrome
    R S Rittmaster
    Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina, USA
    Endocrinol Metab Clin North Am 28:409-21. 1999
    ..Improvement will occur in most women. Unless the underlying cause of the PCOS is corrected, medical therapy will need to be continued indefinitely...
  2. ncbi request reprint Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
    R S Rittmaster
    Department of Medicine and the Queen Elizabeth II Health Sciences Center, Dalhousie University, Halifax, Nova Scotia, Canada
    J Clin Endocrinol Metab 85:2129-34. 2000
    ..This combination of drugs may be a useful approach to maximizing bone density in women with vertebral osteoporosis...
  3. ncbi request reprint The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer
    R S Rittmaster
    Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
    J Urol 162:2165-9. 1999
    ....
  4. ncbi request reprint Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase
    A S Wright
    Department of Physiology and Biophysics, Dalhousie University, Halifax, Nova Scotia, Canada
    Endocrinology 140:4509-15. 1999
    ..In addition, we hypothesize that T has arisen as the major circulating androgen instead of DHT because it can be aromatized to estradiol, which itself has important roles in male reproductive function and bone physiology...
  5. ncbi request reprint Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5
    L N Thomas
    Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
    Prostate 42:203-10. 2000
    ....
  6. ncbi request reprint Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer
    Lynn N Thomas
    Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada
    Prostate 63:231-9. 2005
    ..However, inhibition of both 5alphaR isoenzymes causes a greater decrease in serum DHT. The aim of this study was to assess differential expression of these enzymes at various stages of PCa development...
  7. ncbi request reprint Testolactone-associated high androgen levels, a pharmacologic effect or a laboratory artifact?
    E A Cummings
    Department of Pediatrics, IWK Grace Health Centre, Halifax, Nova Scotia, Canada
    J Clin Endocrinol Metab 83:784-7. 1998
    ..Testolactone, in serial dilutions, cross-reacted in the testosterone assay. Testolactone significantly interferes in these serum RIAs, making their use unreliable in follow-up of patients treated with testolactone...
  8. ncbi request reprint Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line
    C B Lazier
    Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, NS, Canada
    Prostate 58:130-44. 2004
    ..The objective of this study was to compare and contrast the effects of a potent new 5alphaR inhibitor, dutasteride, with finasteride in the LNCaP prostate cancer cell line...